Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients

西那卡塞特 拟钙质 医学 泌尿科 中止 内科学 甲状旁腺切除术 甲状旁腺激素 继发性甲状旁腺功能亢进 内分泌学 血液透析 甲状旁腺功能亢进
作者
Mark D. Danese,Deborah P. Lubeck,Vasily Belozeroff,Tzu‐Chieh Lin,Pooja Desai,Michelle Gleeson,Kévin Martin,Michel Chonchol
出处
期刊:American Journal of Nephrology [Karger Publishers]
卷期号:51 (10): 815-822 被引量:5
标识
DOI:10.1159/000510360
摘要

<b><i>Background:</i></b> Calcimimetics are used to treat mineral and bone disorder by reducing parathyroid hormone (PTH), calcium (Ca), and phosphorus (Phos). The study objectives were to assess the control of PTH, Ca, and Phos over time in patients receiving cinacalcet or etelcalcetide as well as dosing and time to discontinuation for etelcalcetide. <b><i>Methods:</i></b> This was a retrospective cohort study using electronic medical records from small and independent dialysis centers. Adults ≥18 years of age were identified as cinacalcet or etelcalcetide users based on the first calcimimetic received in 2018 (index date). Patients were followed from the index date until parathyroidectomy, kidney transplant, death, or end of data (December 31, 2018). Analyses of mean PTH, Ca, and Phos, as well as target achievement of PTH, Ca, and Phos were conducted over a 9-month period. Discontinuation with etelcalcetide was measured with the Kaplan-Meier estimator. <b><i>Results:</i></b> There were 1,346 cinacalcet patients (mean age 60.5 years, 43.5% female, and 47.1% Black) and 1,255 etelcalcetide patients (mean age 63.4 years, 46.6% female, and 38.5% Black). At baseline, the proportions in target were similar for etelcalcetide versus cinacalcet: 36 versus 38% for PTH, 79 versus 80% for Ca, and 43 versus 44% for Phos. Overall, 40–47% of cinacalcet users and 48–62% of etelcalcetide users were observed to be in target for PTH over 9 months. The proportion in target for Phos ranged from 41 to 46% for cinacalcet and 46–51% for etelcalcetide. The proportion in target for Ca ranged from 74 to 78% for cinacalcet and 60–73% for etelcalcetide. Etelcalcetide 12-month discontinuation was 37.4%. <b><i>Conclusion:</i></b> Both calcimimetics were effective in keeping PTH, Ca, and Phos levels within target. Patients receiving etelcalcetide tended to have lower laboratory values for PTH, Ca, and Phos over time, while patients receiving cinacalcet tended to be more likely to be in target for Ca over time.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
hanchangcun发布了新的文献求助10
刚刚
lwr1234完成签到,获得积分10
刚刚
刚刚
orixero应助present采纳,获得10
1秒前
1秒前
Ju1es完成签到,获得积分10
1秒前
1秒前
KFjiatang完成签到,获得积分10
2秒前
2秒前
kento完成签到,获得积分0
2秒前
starry完成签到,获得积分10
3秒前
3秒前
上官若男应助吴巧采纳,获得10
4秒前
Janmy完成签到,获得积分10
4秒前
4秒前
4秒前
高求完成签到,获得积分10
5秒前
5秒前
耍酷耳机发布了新的文献求助10
5秒前
5秒前
ccfyyds发布了新的文献求助10
5秒前
6秒前
yayaha发布了新的文献求助10
6秒前
绊宸发布了新的文献求助10
6秒前
良致发布了新的文献求助10
6秒前
炙热的雪糕完成签到,获得积分10
7秒前
yeape完成签到,获得积分10
7秒前
7秒前
郭玉强完成签到,获得积分10
7秒前
任成艳发布了新的文献求助10
7秒前
狂野盼雁完成签到,获得积分10
8秒前
yuanyiyuan完成签到,获得积分10
8秒前
Changfh发布了新的文献求助10
8秒前
Elm应助灵萱采纳,获得10
9秒前
9秒前
skxxxxxx发布了新的文献求助10
9秒前
CodeCraft应助呆萌道天采纳,获得10
9秒前
dove完成签到,获得积分10
9秒前
全宝林完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Chemistry and Physics of Carbon Volume 18 800
The Organometallic Chemistry of the Transition Metals 800
Leading Academic-Practice Partnerships in Nursing and Healthcare: A Paradigm for Change 800
The formation of Australian attitudes towards China, 1918-1941 640
Signals, Systems, and Signal Processing 610
全相对论原子结构与含时波包动力学的理论研究--清华大学 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6431487
求助须知:如何正确求助?哪些是违规求助? 8247296
关于积分的说明 17539413
捐赠科研通 5488337
什么是DOI,文献DOI怎么找? 2896251
邀请新用户注册赠送积分活动 1872775
关于科研通互助平台的介绍 1712754